CONVERT trial<br />Concurrent ONce-daily VErsus twice-daily RadioTherapy: A 2-arm randomised controlled trial of concurre
EGFR-targeted treatments: insights from the adjuvant to the resistant setting - memoinOncology
Dacoplice® | Pfizer India | Efficacy
Critical Review of <i>EGFR</i>-Mutated NSCLC: What We Do and Do Not Know - Open Access | healthbook
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials - Annals of Oncology
Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors - Vera Hirsh, 2018
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050) - Lung Cancer
VIZIMPRO® (dacomitinib) Efficacy | Safety Info
Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations | Business Wire
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis | The BMJ
OncoPrescribe - Write The Perfect Prescription
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials - ScienceDirect
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial - Journal of Thoracic Oncology
Summary of median overall survival (OS) and progression-free survival... | Download Table
ASCO Publications on Twitter: "Dacomitinib improves overall survival compared with gefitinib in EGFR-mutant advanced NSCLC https://t.co/1XC2SYYLkG #lcsm… https://t.co/N8dO0uPg7H"
Vizimpro 45 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
References in Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial - The Lancet Oncology
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck† - Annals of Oncology
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial - The Lancet Oncology
Cost‐effectiveness analysis of first‐line treatments for advanced epidermal growth factor receptor‐mutant non‐small cell lung cancer patients - Li - - Cancer Medicine - Wiley Online Library
Dacomitinib in lung cancer: a "lost generation" EGFR tyros | DDDT
PDF) Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
P76.67 Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050 - Journal of Thoracic Oncology
